tetano
Editor, Senior Moderator
iScience
. 2023 Jan 10;105949.
doi: 10.1016/j.isci.2023.105949. Online ahead of print.
An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
Anna Offersgaard[SUP] 1 [/SUP], Carlos Rene Duarte Hernandez[SUP] 1 [/SUP], Shan Feng[SUP] 1 [/SUP], Pavel Marichal-Gallardo[SUP] 2 [/SUP], Kenn Holmbeck[SUP] 1 [/SUP], Anne Finne Pihl[SUP] 1 [/SUP], Carlota Fernandez-Antunez[SUP] 1 [/SUP], Garazi Peña Alzua[SUP] 1 [/SUP], Katrine Top Hartmann[SUP] 3 [/SUP], Long V Pham[SUP] 1 [/SUP], Yuyong Zhou[SUP] 1 [/SUP], Karen Anbro Gammeltoft[SUP] 1 [/SUP], Ulrik Fahnøe[SUP] 1 [/SUP], Uffe Vest Schneider[SUP] 4 [/SUP], Gabriel Kristian Pedersen[SUP] 5 [/SUP], Henrik Elvang Jensen[SUP] 3 [/SUP], Jan Pravsgaard Christensen[SUP] 6 [/SUP], Santseharay Ramirez[SUP] 1 [/SUP], Jens Bukh[SUP] 1 [/SUP], Judith Margarete Gottwein[SUP] 1 [/SUP]
Affiliations
Abstract
Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralising antibodies in mice; moreover, lyophilised antigen was immunogenic. Upon homologous challenge, I-SARS-CoV-2 immunised hamsters were protected against disease and lung pathology. In contrast to reports for widely used vaccines, hamster plasma similarly neutralised the homologous and the Delta (B.1.617.2) variant viruses, while the Omicron (B.1.1.529) variant was neutralised less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.
. 2023 Jan 10;105949.
doi: 10.1016/j.isci.2023.105949. Online ahead of print.
An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
Anna Offersgaard[SUP] 1 [/SUP], Carlos Rene Duarte Hernandez[SUP] 1 [/SUP], Shan Feng[SUP] 1 [/SUP], Pavel Marichal-Gallardo[SUP] 2 [/SUP], Kenn Holmbeck[SUP] 1 [/SUP], Anne Finne Pihl[SUP] 1 [/SUP], Carlota Fernandez-Antunez[SUP] 1 [/SUP], Garazi Peña Alzua[SUP] 1 [/SUP], Katrine Top Hartmann[SUP] 3 [/SUP], Long V Pham[SUP] 1 [/SUP], Yuyong Zhou[SUP] 1 [/SUP], Karen Anbro Gammeltoft[SUP] 1 [/SUP], Ulrik Fahnøe[SUP] 1 [/SUP], Uffe Vest Schneider[SUP] 4 [/SUP], Gabriel Kristian Pedersen[SUP] 5 [/SUP], Henrik Elvang Jensen[SUP] 3 [/SUP], Jan Pravsgaard Christensen[SUP] 6 [/SUP], Santseharay Ramirez[SUP] 1 [/SUP], Jens Bukh[SUP] 1 [/SUP], Judith Margarete Gottwein[SUP] 1 [/SUP]
Affiliations
- PMID: 36644321
- PMCID: PMC9829433
- DOI: 10.1016/j.isci.2023.105949
Abstract
Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralising antibodies in mice; moreover, lyophilised antigen was immunogenic. Upon homologous challenge, I-SARS-CoV-2 immunised hamsters were protected against disease and lung pathology. In contrast to reports for widely used vaccines, hamster plasma similarly neutralised the homologous and the Delta (B.1.617.2) variant viruses, while the Omicron (B.1.1.529) variant was neutralised less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.